Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is poised for significant growth due to its focus on developing MasterKey therapies that target oncogenic mutations, particularly with promising compounds BDTX-4933 and BDTX-1535. The company anticipates achieving a favorable Overall Response Rate (ORR) in the second half of 2025, which could translate into forecasted sales of approximately $500 to $750 million, indicating strong revenue potential. Furthermore, M&A proxy valuations for similar oncology acquisitions suggest a prospective upside of 3 to 6 times from current levels, further enhancing the company's appeal to investors.

Bears say

Black Diamond Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential underdosing issues with its therapeutics, which could hinder efficacy outcomes. Additionally, concerns regarding the Phase 3 trial's enrollment of a representative patient population raise the risk of reduced efficacy, particularly for its candidate therapies, BDTX-4933 and BDTX-1535. Furthermore, the company faces multiple threats including disappointing safety and efficacy results, potential delays in research and development, increased competition in its target market, and difficulties in securing adequate funding for ongoing projects.

BDTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, BDTX has a Strong Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.